New Opportunities for Targeting Therapy in HER2-Positive Breast Cancer
After completing this activity, participants will be able to:
- Review the clinical trial data on treatment pathways and associated new/emerging targets for the treatment of patients with HER2-positive breast cancer;
- Discuss the mechanisms of action and clinical role of monoclonal antibodies, tyrosine kinase inhibitors (TKIs), an antibody-drug conjugate (ADC) therapy in the treatment of HER2-positive breast cancer;
- Identify strategies for managing/preventing treatment-related adverse events (TRAEs) and improving outcomes in patients with HER2-positive breast cancer.
Learners can attend this conference in person or virtually.
WANT TO KNOW MORE?
The University of Chicago reserves the right to cancel or postpone this conference due to unforeseen circumstances. In the unlikely event this activity must be cancelled or postponed, the registration fee will be refunded; however, The University of Chicago is not responsible for any related costs, charges, or expenses to participants, including fees assessed by airline/travel/lodging agencies.
Breast Cancer Medicine
New York Oncology Hematology
Albany, New York
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The University of Chicago Pritzker School of Medicine and New York Oncology Hematology, PC, and in collaboration with my myMedEd, Inc. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The University Of Chicago Pritzker School Of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.